Marked elevation of serum macrophage migration inhibitory factor levels in patients with pemphigus vulgaris

International Journal of Dermatology

Volumn 49, Issue 2, 2010, Pages 146-148

  Namazi, Mohammad Reza ^b   Fallahzadeh, Mohammad Kazem ^b   Shaghelani, Hassan ^a   Kamali Sarvestani, Eskandar ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; MACROPHAGE MIGRATION INHIBITION FACTOR;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOPATHOGENESIS; MALE; PEMPHIGUS VULGARIS; PROTEIN BLOOD LEVEL; T LYMPHOCYTE ACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CASE-CONTROL STUDIES; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; PEMPHIGUS; PROBABILITY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 74949104832     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2009.04238.x     Document Type: Article

References (33)

1. Bystryn JC, Rudolph JL. Pemphigus. Lancet 2005, 366:61-73.
2. Wojnarowska F, Venning VA, Burge SM, Burns T, Breathnach SM, Cox N, Griffiths C. Immunobullous Diseases. Rook's Textbook of Dermatology 2004, 41.5-41.7. In, eds, 7th edn, Oxford, Blackwell Scientific Publications
3. Baroni A, Lanza A, Cirillo N. Vesicular and bullous disorders: pemphigus. Dermatol Clin 2007, 25:597-603.
4. Goldstien BG, Goldstein AO. Pemphigus. http://www.uptodate.com/online/content/topic.do?topicKey=pri_derm/10427&selectedTitle=1~51&source=search_result, Uptodate 16.2 online. [WWW document]. URL: [Accessed on: October 1, 2008]
5. Morand EF. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor. Intern Med J 2005, 35:419-426.
6. Stosic-Grujicic S, Stojanovic I, Nicoletti F. MIF in autoimmunity and novel therapeutic approaches. Autoimmun Rev. 2009, 8:244-249.
7. Kudrin A, Ray D. Cunning factor: macrophage migration inhibitory factor as a redox-regulated target. Immunol Cell Biol 2008, 86:232-238.
8. Calanda T, Bernhagen J, Mitchell RA. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 1994, 179:1895-1902.
9. Nakamaru Y, Oridate N, Nishihira J. Macrophage migration inhibitory factor (MIF) contributes to the development of allergic rhinitis. Cytokine 2005, 31:103-108.
10. Shimizu T. Role of macrophage migration inhibitory factor (MIF) in the skin. J Dermatol Sci 2005, 37:65-73.
11. Kim HR, Park MK, Cho ML. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis. J Rheumatol 2007, 34:927-936.
12. Foote A, Briganti EM, Kipen Y. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004, 31:268-273.
13. Shimizu T, Nishihira J, Mizue Y. High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J Invest Dermatol 2001, 116:989-990.
14. Shimizu T, Abe R, Ohkawara A. Macrophage migration inhibitory factor is an essential immunoregulatory cytokine in atopic dermatitis. Biochem Biophys Res Commun 1997, 240:173-178.
15. Asano Y, Makino T, Norisugi O. Macrophage migration inhibitory factor (MIF) in bullous pemphigoid. J Dermatol Sci 2008, 49:95-97.
16. Brenner S, Livni E. Macrophage migration inhibition factor in pemphigus vulgaris. J Am Acad Dermatol 1986, 14:453-455.
17. Bhol K, Mohimen A, Ahmed AR. Correlation of subclasses of IgG with disease activity in pemphigus vulgaris. Dermatology 1994, 189(Suppl 1):85-89.
18. Bhol K, Natarajan K, Nagarwalla N. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A 1995, 92:5239-5243.
19. Hertl M, Veldman C. T-cellular autoimmunity against desmogleins in pemphigus, an autoantibody-mediated bullous disorder of the skin. Autoimmun Rev 2003, 2:278-283.
20. Echigo T, Hasegawa M, Shimada Y. Both Th1 and Th2 chemokines are elevated in sera of patients with autoimmune blistering diseases. Arch Dermatol Res 2006, 298:38-45.
21. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. Dermatol Clin 1993, 11:429-452.
22. Narbutt J, Lukamowicz J, Bogaczewicz J. Serum concentration of interleukin-6 is increased both in active and remission stages of pemphigus vulgaris. Mediators Inflamm 2008, 2008. 875394
23. Feliciani C, Toto P, Wang B. Urokinase plasminogen activator mRNA is induced by IL-1alpha and TNF-alpha in in vitro acantholysis. Exp Dermatol 2003, 12:466-471.
24. Feliciani C, Toto P, Amerio P. In vitro and in vivo expression of interleukin-1α and tumor necrosis factor-α mRNA in pemphigus vulgaris: interleukin-1alpha and tumor necrosis factor-alpha are involved in acantholysis. J Invest Dermatol 2000, 114:71-77.
25. D'Auria L, Bonifati C, Mussi A. Cytokines in the sera of patients with pemphigus vulgaris: interleukin-6 and tumour necrosis factor-alpha levels are significantly increased as compared to healthy subjects and correlate with disease activity. Eur Cytokine Netw 1997, 8:383-387.
26. Jacobi A, Shuler G, Hertl M. Rapid control of therapy-refractory pemphigus vulgaris by treatment with the tumour necrosis factor-alpha inhibitor infliximab. Br J Dermatol 2005, 153:448-449.
27. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. Cutis 2004, 74:245-247.
28. Larson DF, Horak K. Macrophage migration inhibitory factor: controller of systemic inflammation. Crit Care 2006, 10:138.
29. Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 2003, 3:791-800.
30. Ayoub S, Hickey MJ, Morand EF. Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis. Nat Clin Pract Rheumatol 2008, 4:98-105.
31. Gore Y, Starlets D, Maharshak N. Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 2008, 283:2784-2792.
32. Bacher M, Metz CN, Calandra T. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 1996, 93:7849-7854.
33. Javeed A, Zhao Y, Zhao Y. Macrophage-migration inhibitory factor: role in inflammatory diseases and graft rejection. Inflamm Res 2008, 57:45-50.